PEP/NEWS — Peptide intel. Daily.

Your brain is a garden. And most people are letting weeds take over while their hippocampus quietly shrinks year after year. In this clip from The Human Upgrade, Dave Asprey sits down with Dr. Majid Fotuhi, a neuroscientist and neurologist

Attia's AMA #86 walks through updated evidence on lean mass loss during GLP-1 therapy. The central finding: structured resistance training and adequate protein intake largely protect muscle — changing how clinicians should counsel patients on semaglutide and tirzepatide.

Bryan Johnson outlines four cardiovascular protocols that have pushed his blood pressure into the bottom 10% of 18-year-olds. The piece is data-driven and benchmarks against published age-matched norms — not self-reported impressions.

Lifespan.io's monthly digest covers the biggest aging-research moves in June 2026. Genomic-level interventions dominated — from telomere signaling to senolytic targets — with several findings that carry direct peptide-adjacent implications.

Researchers mapped aging trajectories at the individual cell-type level and found predictive power for Alzheimer's disease and lung cancer onset. Organ-level biological age clocks are becoming clinically useful tools, not just academic curiosities.

NeuroAge Therapeutics is running a structured competition to reverse biological age over six months, with clinical-grade baseline and follow-up testing. Baseline kits ship in September — this is one of the first formalized real-world trials of competing longevity protocols.

SystemAge 2.1 introduces separate biological age models for male and female subjects. The update reflects growing evidence that aging trajectories differ significantly by sex — a gap that single-model clocks have consistently underestimated.

Lancôme has partnered with Swiss longevity biotech to bring Mitopure (a mitochondria-targeting urolithin A compound) into a consumer skincare range. The launch includes a skin biological age assessment — a rare move that ties cosmetic marketing to measurable biomarkers.

Part one of a three-part deep dive maps how cancers start and which molecular pathways tumors exploit. It sets the foundation for evaluating where peptides might help — and where they could pose risk — in oncology contexts.

RNA-DNA hybrids accumulating in the cytoplasm of senescent cells appear to trigger the SASP (senescence-associated secretory phenotype) — the inflammatory broadcast that makes aged cells harmful to surrounding tissue. The finding points to a new druggable target upstream of inflammation.